Machida S - Search Results

1

Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens.

Takei Y, Takahashi Y, Machida S, Taneichi A, Takahashi S, Nagashima T, Morisawa H, Saga Y, Matsubara S, Fujiwara H. Takei Y, et al. Among authors: machida s. J Obstet Gynaecol Res. 2017 Feb;43(2):358-364. doi: 10.1111/jog.13203. Epub 2016 Dec 9. J Obstet Gynaecol Res. 2017. PMID: 27935223

2

Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer.

Machida S, Takei Y, Yoshida C, Takahashi Y, Koyanagi T, Sato N, Taneichi A, Saga Y, Fujiwara H, Suzuki M. Machida S, et al. Oncology. 2014;86(4):232-8. doi: 10.1159/000357269. Epub 2014 May 13. Oncology. 2014. PMID: 24853194

3

Immature ovarian teratoma with hyponatremia and low serum vasopressin level.

Sakamoto Y, Takei Y, Saga Y, Machida S, Takahashi Y, Fujiwara H. Sakamoto Y, et al. Among authors: machida s. J Obstet Gynaecol Res. 2016 Oct;42(10):1400-1404. doi: 10.1111/jog.13057. Epub 2016 Jun 9. J Obstet Gynaecol Res. 2016. PMID: 27277383

4

Prognosis of endometrial cancer patients with and without symptoms at recurrence.

Yoshiba T, Takei Y, Machida S, Taneichi A, Sato N, Takahashi S, Takahashi Y, Saga Y, Matsubara S, Fujiwara H. Yoshiba T, et al. Among authors: machida s. J Obstet Gynaecol Res. 2016 Dec;42(12):1814-1821. doi: 10.1111/jog.13112. Epub 2016 Aug 16. J Obstet Gynaecol Res. 2016. PMID: 27526662

5

Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.

Takei Y, Takahashi S, Machida S, Taneichi A, Yoshiba T, Takahashi Y, Yoshida C, Saga Y, Matsubara S, Fujiwara H. Takei Y, et al. Among authors: machida s. Int J Clin Oncol. 2018 Oct;23(5):930-935. doi: 10.1007/s10147-018-1280-9. Epub 2018 Apr 20. Int J Clin Oncol. 2018. PMID: 29679177

6

Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine.

Takahashi Y, Takei Y, Machida S, Taneichi A, Takahashi S, Yoshiba T, Koyanagi T, Tamura K, Saga Y, Fujiwara H. Takahashi Y, et al. Among authors: machida s. J Obstet Gynaecol Res. 2021 Feb;47(2):551-559. doi: 10.1111/jog.14558. Epub 2020 Nov 4. J Obstet Gynaecol Res. 2021. PMID: 33145906

7

A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.

Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno T, Machida S, Sato I. Takei Y, et al. Among authors: machida s. Oncol Rep. 2003 Jul-Aug;10(4):951-5. Oncol Rep. 2003. PMID: 12792751 Clinical Trial.

8

Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.

Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, Kita T, Kikuchi Y, Komiyama S, Mikami M, Suzuki M. Machida S, et al. Oncology. 2003;65(2):102-7. doi: 10.1159/000072333. Oncology. 2003. PMID: 12931014 Clinical Trial.

9

Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.

Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M. Nonaka H, et al. Among authors: machida s. Int J Oncol. 2011 Jan;38(1):113-20. Int J Oncol. 2011. PMID: 21109932

10

Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations.

Sato N, Saga Y, Mizukami H, Wang D, Fujiwara H, Takei Y, Machida S, Ozawa K, Suzuki M. Sato N, et al. Among authors: machida s. Oncol Rep. 2012 May;27(5):1336-40. doi: 10.3892/or.2012.1626. Epub 2012 Jan 11. Oncol Rep. 2012. PMID: 22246397

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

546 results

Search Page